MX2024000233A - Polipeptidos regenerativos y usos de los mismos. - Google Patents
Polipeptidos regenerativos y usos de los mismos.Info
- Publication number
- MX2024000233A MX2024000233A MX2024000233A MX2024000233A MX2024000233A MX 2024000233 A MX2024000233 A MX 2024000233A MX 2024000233 A MX2024000233 A MX 2024000233A MX 2024000233 A MX2024000233 A MX 2024000233A MX 2024000233 A MX2024000233 A MX 2024000233A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- amino acid
- acid sequence
- soft
- tissue
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000001172 regenerating effect Effects 0.000 title 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 2
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 abstract 2
- 208000016247 Soft tissue disease Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
- 101150002416 Igf2 gene Proteins 0.000 abstract 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000015357 muscle tissue disease Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 150000004666 short chain fatty acids Chemical class 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163259088P | 2021-06-21 | 2021-06-21 | |
| PCT/US2022/033059 WO2022271466A1 (en) | 2021-06-21 | 2022-06-10 | Regenerative polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000233A true MX2024000233A (es) | 2024-03-14 |
Family
ID=84543438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000233A MX2024000233A (es) | 2021-06-21 | 2022-06-10 | Polipeptidos regenerativos y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220409696A1 (enExample) |
| EP (1) | EP4359425B1 (enExample) |
| JP (1) | JP2024525213A (enExample) |
| KR (1) | KR20240029031A (enExample) |
| CN (1) | CN117999278A (enExample) |
| AU (1) | AU2022298470A1 (enExample) |
| CA (1) | CA3223707A1 (enExample) |
| IL (1) | IL309562A (enExample) |
| MX (1) | MX2024000233A (enExample) |
| WO (1) | WO2022271466A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| AU2024337423A1 (en) * | 2023-09-07 | 2026-03-19 | Juvena Therapeutics, Inc. | Igf2 fusion protein formulations and therapeutic uses thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5155038A (en) | 1990-02-22 | 1992-10-13 | W. R. Grace & Co.-Conn. | Use of thrombospondin to promote wound healing |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| SE9101840L (sv) * | 1991-06-14 | 1992-12-15 | Kabi Pharmacia | Ny medicinsk anvaendning |
| US5736363A (en) | 1991-07-29 | 1998-04-07 | British Bio-Technology Limited | IGF-II analogues |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| ES2174852T3 (es) | 1992-08-26 | 2002-11-16 | Celtrix Pharma | Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos. |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5622932A (en) | 1995-05-05 | 1997-04-22 | Eli Lilly And Company | IGF-1 superagonists |
| GB9608130D0 (en) | 1996-04-19 | 1996-06-26 | Univ Sheffield | Adam proteins and uses thereof |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| TWI233361B (en) | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| CN101172091B (zh) | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| US7837993B2 (en) | 2004-03-19 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regeneration of aged skeletal muscle tissues |
| AU2006203882B2 (en) | 2005-01-07 | 2011-05-12 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
| EP2236153A3 (en) * | 2005-01-25 | 2012-08-22 | Five Prime Therapeutics, Inc. | Compositons and methods for treating cardiac conditions |
| US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| EP2474318A1 (en) * | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US9226965B2 (en) | 2007-10-05 | 2016-01-05 | U.S. Department Of Veterans Affairs | Method and composition for treating heart failure |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| KR20100119437A (ko) | 2009-04-30 | 2010-11-09 | 충북대학교 산학협력단 | 인슐린 유사 성장 인자 ⅱ를 이용하여 세포 분화를 조절하는 방법 |
| US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| BR112012033214B1 (pt) | 2010-06-25 | 2020-11-03 | Shire Human Genetic Therapies, Inc. | uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente |
| WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| WO2013166156A2 (en) | 2012-05-01 | 2013-11-07 | The Johns Hopkins University | Compositions and methods for treating or preventing osteoarthritis |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| ES2679374T3 (es) | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| SG11201503782PA (en) | 2012-12-18 | 2015-06-29 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| WO2014152440A2 (en) | 2013-03-15 | 2014-09-25 | Trustees Of Boston University | Polymorphism of thrombospondin-1 as a biomarker for susceptibility to dry eye |
| US9758763B2 (en) | 2013-05-29 | 2017-09-12 | The Regents Of The University Of California | Methods and compositions for somatic cell proliferation and viability |
| JP2016535080A (ja) | 2013-10-02 | 2016-11-10 | ノバルティス アーゲー | 療法における使用のためのインスリン様成長因子模倣物 |
| US10265372B2 (en) | 2014-08-12 | 2019-04-23 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| US10654912B2 (en) | 2015-09-08 | 2020-05-19 | Jcr Pharmaceuticals Co., Ltd. | Human serum albumin mutant |
| CA3000742A1 (en) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| CN109312338B (zh) * | 2015-10-30 | 2022-09-27 | 爱迪塔斯医药公司 | 治疗单纯疱疹病毒的crispr/cas相关方法及组合物 |
| EP3419651B1 (en) * | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| GB201620119D0 (en) | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| WO2018189661A2 (en) | 2017-04-10 | 2018-10-18 | Palti Yoram Prof | Methods and compounds for treating diabetes |
| CN110997708A (zh) | 2017-04-27 | 2020-04-10 | 礼来公司 | 人bmp7蛋白的变体 |
| US20190240156A1 (en) | 2018-02-06 | 2019-08-08 | Agency For Science, Technology And Research (A*Star) | Therapeutic Compositions Comprising Mesenchymal Stem Cell Particles And Related Methods |
| EP3762505A4 (en) * | 2018-03-09 | 2021-12-01 | Avrobio, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE |
| TW202344691A (zh) | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| EP4606428A3 (en) * | 2018-06-27 | 2025-11-05 | Juvena Therapeutics, Inc. | Heparin-associated polypeptides and uses thereof |
| EP3897747A4 (en) | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| EP3917539A4 (en) * | 2019-02-01 | 2022-11-23 | Avrobio, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS |
| JP2022552254A (ja) | 2019-10-10 | 2022-12-15 | アミカス セラピューティックス インコーポレイテッド | バリアントｉｇｆ２構築体 |
| WO2021133858A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics, Inc. | Heparin-associated polypeptides and uses thereof |
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| EP4171658A4 (en) | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| US20220031812A1 (en) | 2020-07-30 | 2022-02-03 | Silver Creek Pharmaceuticals, Inc. | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders |
| PE20231680A1 (es) | 2021-02-17 | 2023-10-19 | Dr Falk Pharma Gmbh | Anticuerpos anti-cd30l y usos de estos |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| EP4359430A4 (en) | 2021-06-23 | 2025-07-16 | Lycia Therapeutics Inc | BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES |
| US20230405089A1 (en) | 2022-06-17 | 2023-12-21 | Juvena Therapeutics, Inc. | Heparin-Associated Polypeptides and Uses Thereof |
-
2022
- 2022-06-10 EP EP22829009.4A patent/EP4359425B1/en active Active
- 2022-06-10 CA CA3223707A patent/CA3223707A1/en active Pending
- 2022-06-10 MX MX2024000233A patent/MX2024000233A/es unknown
- 2022-06-10 CN CN202280057157.0A patent/CN117999278A/zh active Pending
- 2022-06-10 JP JP2023579375A patent/JP2024525213A/ja active Pending
- 2022-06-10 KR KR1020247002131A patent/KR20240029031A/ko active Pending
- 2022-06-10 AU AU2022298470A patent/AU2022298470A1/en active Pending
- 2022-06-10 US US17/837,920 patent/US20220409696A1/en not_active Abandoned
- 2022-06-10 WO PCT/US2022/033059 patent/WO2022271466A1/en not_active Ceased
- 2022-06-10 IL IL309562A patent/IL309562A/en unknown
-
2024
- 2024-05-13 US US18/662,443 patent/US12329801B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024525213A (ja) | 2024-07-10 |
| US20240294597A1 (en) | 2024-09-05 |
| EP4359425A4 (en) | 2025-04-09 |
| CN117999278A (zh) | 2024-05-07 |
| US20220409696A1 (en) | 2022-12-29 |
| EP4359425A1 (en) | 2024-05-01 |
| AU2022298470A1 (en) | 2024-02-01 |
| CA3223707A1 (en) | 2022-12-29 |
| US12329801B2 (en) | 2025-06-17 |
| IL309562A (en) | 2024-02-01 |
| EP4359425B1 (en) | 2026-08-05 |
| KR20240029031A (ko) | 2024-03-05 |
| WO2022271466A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2864360B1 (en) | Targeted therapeutics | |
| SA521430398B1 (ar) | Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد | |
| JP2541761B2 (ja) | ミュレル管抑制物質様ポリペプチドおよびその製造方法 | |
| KR100345254B1 (ko) | 생물학적샘플속의인터루킨12또는인터루킨12의p40아단위를검출하는방법 | |
| ZA200908445B (en) | Reconstituted surfactants having improved properties | |
| JP6786544B2 (ja) | 成長ホルモン断片の使用 | |
| JP2010538030A (ja) | 機能障害性シナプス伝達に伴う障害の治療用ｇｉｐの使用 | |
| JP4541899B2 (ja) | ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ | |
| RU2015122887A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПОВЫШЕНИЯ РЕПРОДУКТИВНОЙ АКТИВНОСТИ У МЛЕКОПИТАЮЩИХ, НЕ ЯВЛЯЮЩИХСЯ ЧЕЛОВЕКОМ, С ПРИМЕНЕНИЕМ БИОЛОГИЧЕСКИ АКТИВНОГО РЕКОМБИНАНТНОГО ФОЛЛИКУЛОСТИМУЛИРУЮЩЕГО ГОРМОНА (rFSH) | |
| WO2005094890A1 (ja) | 身長増加用組成物 | |
| ZA202301784B (en) | Crf2 receptor agonists and their use in therapy | |
| RU2432360C2 (ru) | Вариант еро, обладающий повышенным сродством связывания с рецептором и сниженным антигенным потенциалом, днк, кодирующая такой вариант еро, рекомбинантный экспрессионный вектор, содержащий такую днк, клетка-хозяин, трансформированная или трансфектированная таким вектором, способ получения такого варианта еро и фармацевтическая композиция, содержащая такой вариант еро | |
| WO2021251673A1 (ko) | 치주질환 또는 탈구성 외상 치아의 예방 또는 치료용 약학 조성물 | |
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| Gelato | Growth hormone-insulinlike growth factor I and immune function | |
| NZ209078A (en) | Growth hormone-releasing peptides and compositions | |
| RU97107853A (ru) | Пептидная специфичность антител к мвр (миелиновому основному белку), содержащая его фармацевтическая композиция и способ лечения рассеянного склероза | |
| KR20080038391A (ko) | 페그화 성장 호르몬의 액체 제제 | |
| WO2023122280A3 (en) | Compositions and methods for treating skin defects | |
| JP2021516222A5 (enExample) | ||
| HUT77979A (hu) | Peptidek, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| EP4180452A1 (en) | Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereof | |
| JP2024525213A (ja) | 再生ポリペプチドおよびその使用 | |
| Leung et al. | Purification and physiochemical properties of a recombinant bovine growth hormone produced by cultured murine fibroblasts | |
| Srivastava et al. | A new target for growth hormone releasing-hormone action in rat: the Sertoli cell |